Sbir phase I
Ended Definitive Contract Awarded Last action
- Contract number
- 75N93022C00029
- Awardee
-
Neovaxsyn Inc. UEI EHMTBALCKFE8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $300,000
Award facts
- Opportunity
-
- A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals Pre-Solicitation · PHS20221 · Posted Jul 12, 2021
- Contract value 100% obligated
- $300,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Ames, IA 50014, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $300,000 |
About this award
Neovaxsyn Inc., a minority-owned small disadvantaged business based in Ames, Iowa, was awarded a $300,000 Small Business Innovation Research (SBIR) Phase I contract by the National Institute of Allergy and Infectious Diseases (NIAID) on July 1, 2022. The contract, designated as a total small business set-aside, has an ultimate completion date of September 30, 2025 and is structured as a firm fixed-price definitive contract. The award originated from a pre-solicitation notice issued by the National Institutes of Health and Centers for Disease Control and Prevention seeking innovative research proposals to advance infectious disease and public health missions, with proposals evaluated under NAICS codes 541711 and 541712.
Neovaxsyn's contract work focuses on biotechnology research and development within the infectious disease domain, leveraging the company's specialized expertise in HIV/AIDS vaccine technologies. The company utilizes advanced nanotechnology and immunological approaches to develop potential medical countermeasures, with particular emphasis on developing next-generation immunoprevention platforms against HIV-1. This SBIR Phase I award supports the company's ongoing research initiatives aimed at eliciting broadly neutralizing antibodies through innovative vaccine strategies, contributing to NIAID's mission to conduct and support research on infectious diseases affecting millions globally.
Quick answers
Who was awarded contract 75N93022C00029?
75N93022C00029 was awarded to Neovaxsyn Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2022.
How much is contract 75N93022C00029 worth?
The government has obligated $300,000 on 75N93022C00029.
Was contract 75N93022C00029 competed?
The extent of competition for 75N93022C00029 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award